RxDoctor Payments Data

Aref Wappi, MD

Internal Medicine · Bonita Springs, FLNPI 1023026184

Payments from drug & device makers

$1,601in general payments, 2019–2025

Across 66 payments — averaging $24.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$377
  • AstraZeneca$308
  • Amarin Pharma, Inc.$170
  • Lilly USA, LLC$129
  • Lundbeck LLC$127
  • Amgen$101
  • plus $388 from 10 others

What the payments were for

  • Food & beverage$1,594100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,601 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$422,811
Medicare patients
628
Services billed
5,281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin169$217,177
OzempicSemaglutide110$147,040
EliquisApixaban93$122,369
MounjaroTirzepatide78$94,476
XareltoRivaroxaban53$76,355
FarxigaDapagliflozin Propanediol53$64,782
DovatoDolutegravir Sodium/Lamivudine14$41,316
GemtesaVibegron28$36,804
JanuviaSitagliptin Phosphate22$35,781
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$23,663
EntrestoSacubitril/Valsartan16$22,987
Tresiba Flextouch U-100Insulin Degludec22$16,408
MyrbetriqMirabegron18$15,964
Repatha SyringeEvolocumab12$13,020
Breo ElliptaFluticasone/Vilanterol12$11,580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$21$217,177169 claims
Novo NordiskOzempic$18$147,040110 claims
PfizerEliquis$91$122,36993 claims
Lilly USA, LLCMounjaro$129$94,47678 claims
AstraZenecaFarxiga$308$64,78253 claims
Sumitomo Pharma America, Inc.Gemtesa$25$36,80428 claims
GSKTrelegy Ellipta, Breo Ellipta$377$35,24325 claims
NovartisEntresto$44$22,98716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Bonita Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →